EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Coumarin‐Based Aldo‐Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors

Sravan K Jonnalagadda, Ling Duan, Louise F Dow, Geetha P Boligala, Elizabeth Kosmacek, Kristyn McCoy, Rebecca Oberley-Deegan, Yashpal Singh Chhonker, Darryl J Murry, C Patrick Reynolds, Barry J Maurer, Trevor M Penning und 1 weitere

ChemMedChem · 04.11.2024 · 19 (21)

DOI: 10.1002/cmdc.202400081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 16.09.2024. Verfasst von Sravan K Jonnalagadda und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States. Hauptthemen laut MEDLINE: Coumarins, Aldo-Keto Reductase Family 1 Member C3, Enzyme Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIEHS NIH HHS, NCI NIH HHS, National Institute of Environmental Health Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of 7‐substituted coumarin derivatives have been characterized as pan‐aldo‐keto reductase family 1C (AKR1C) inhibitors. The AKR1C family of enzymes are overexpressed in numerous cancers where they are involved in drug resistance development. 7‐hydroxy coumarin ethyl esters and their corresponding amides have high potency for AKR1C3 and AKR1C2 inhibition. Coumarin amide 3 a possessed IC 50 values of 50 nM and 90 nM for AKR1C3 and AKR1C2, respectively, and exhibits ‘drug‐like’ metabolic stability and half‐life in human and mouse liver microsomes and plasma. Compound 3 a was employed as a chemical tool to determine pan‐AKR1C2/3 inhibition effects both as a radiation sensitizer and as a potentiator of chemotherapy cytotoxicity. In contrast to previously reported pan‐AKR1C inhibitors, 3 a demonstrated no radiation sensitization effect in a radiation‐resistant prostate cancer cell line model. Pan‐AKR1C inhibition also did not potentiate the in vitro cytotoxicity of ABT‐737, daunorubicin or dexamethasone, in two patient‐derived T‐cell ALL and pre‐B‐cell ALL cell lines. In contrast, a highly selective AKR1C3 inhibitor, compound K90 , enhanced the cytotoxicity of both ABT‐737 and daunorubicin in the T‐cell ALL cell line model. Thus, the inhibitory profile required to enhance chemotherapeutic cytotoxicity in leukemia may be AKR1C isoform and drug specific.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CoumarinsAldo-Keto Reductase Family 1 Member C3Enzyme InhibitorsHumansAnimalsStructure-Activity RelationshipMiceCell Line, TumorAntineoplastic AgentsMolecular StructureDrug Screening Assays, AntitumorDose-Response Relationship, DrugHydroxyprostaglandin DehydrogenasesCell ProliferationMicrosomes, Liver3-Hydroxysteroid DehydrogenasesHydroxysteroid Dehydrogenases3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)

Stichwörter der Autor:innen

AKR1C2 InhibitorAKR1C3 InhibitorDrug ResistanceLeukemiaProstate Cancer

Substanzen

CoumarinsAldo-Keto Reductase Family 1 Member C3Enzyme InhibitorsAntineoplastic AgentsHydroxyprostaglandin Dehydrogenases3-Hydroxysteroid DehydrogenasesHydroxysteroid DehydrogenasesAKR1C3 protein, humanAKR1C2 protein, human3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States.
  • Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States.
  • School of Medicine Cancer Center, Texas Tech University Health Sciences Center, Lubbock, Texas, 79430, United States.
  • Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States.
  • Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States.
  • Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68106, USA.

ORCID-Profile: Paul C Trippier

Förderung

  • NIEHS NIH HHS
  • NCI NIH HHS
  • National Institute of Environmental Health Sciences

Zitieren

APA

Jonnalagadda, S. K., Duan, L., Dow, L. F., Boligala, G. P., Kosmacek, E., McCoy, K., Oberley-Deegan, R., Chhonker, Y. S., Murry, D. J., Reynolds, C. P., Maurer, B. J., Penning, T. M., & Trippier, P. C. (2024). Coumarin‐Based Aldo‐Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors. ChemMedChem, 19(21). https://doi.org/10.1002/cmdc.202400081

Vancouver

Jonnalagadda SK, Duan L, Dow LF, Boligala GP, Kosmacek E, McCoy K, et al. Coumarin‐Based Aldo‐Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors. ChemMedChem. 2024;19(21). doi:10.1002/cmdc.202400081

BibTeX
@article{Jonnalagadda2024,
  author = {Jonnalagadda, Sravan K and Duan, Ling and Dow, Louise F and Boligala, Geetha P and Kosmacek, Elizabeth and McCoy, Kristyn and Oberley-Deegan, Rebecca and Chhonker, Yashpal Singh and Murry, Darryl J and Reynolds, C Patrick and Maurer, Barry J and Penning, Trevor M and Trippier, Paul C},
  title = {Coumarin‐Based Aldo‐Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors},
  journal = {ChemMedChem},
  year = {2024},
  volume = {19},
  number = {21},
  doi = {10.1002/cmdc.202400081}
}
Kostenlos starten →